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Abstract
The cost of next-generation sequencing is now approaching that of the first generation of genome-wide single-
nucleotide genotyping panels, but this is still out of reach for large-scale epidemiologic studies with tens of
thousands of subjects. Furthermore, the anticipated yield of millions of rare variants poses serious challenges for
distinguishing causal from noncausal variants for disease. We explore the merits of using family-based designs for
sequencing substudies to identify novel variants and prioritize them for their likelihood of causality. While the
sharing of variants within families means that family-based designs may be less efficient for discovery than
sequencing of a comparable number of unrelated individuals, the ability to exploit cosegregation of variants with
disease within families helps distinguish causal from noncausal ones. We introduce a score test criterion for
prioritizing discovered variants in terms of their likelihood of being functional. We compare the relative statistical
efficiency of 2-stage versus1-stage family-based designs by application to the Genetic Analysis Workshop 18
simulated sequence data.
Background
Most genome-wide association studies for discovering
common variants associated with disease traits have been
conducted using a case-control design with unrelated
controls. Not only are unrelated individuals easier to
identify and enroll than are entire families (particularly
multiple-case families), but the statistical efficiency per
subject genotyped is typically higher using unrelated con-
trols than using unaffected siblings or other relatives [1].
However, with the growing interest in rare variants and
the availability of next-generation sequencing technology,
there has been a resurgence of interest in using family-
based designs [2-5]. Althoughfamily-based designs are
less efficient for discovering novel variants than designs
using unrelated individuals with the same total number
of subjects, they may have other advantages that may
outweigh this limitation. Specifically, by exploiting infor-
mation about cosegregation with disease within families,
they may be more efficient at prioritizing potentially cau-
sal variants from noncausal ones for subsequent testing
for association with disease in larger samples. The ability
to exploit mendelian inheritance may also substantially
improve the imputation of rare variants in untested sam-
ples [6]. Finally, family-based designs can exploit both
between-family and within-family comparisons in various
2-stage designs for better power while being robust to
bias from population stratification [7-11]. The net result
could be improved power for the ultimate goal of disco-
vering novel associations with disease. We focus here on
the first of these advantages.
Methods
Study designs
We consider a 2-stage design using individuals from a
family study for discovery of novel variants and screen-
ing, followed by association testing in an independent
data set using the linear regression of the phenotype on
the genotype. A subset of members is selected for
sequencing, preferentially sampling those with the most
extreme phenotypes. We rank all the variants identified
in these individuals using a novel score test and select
those most likely to be causal for genotyping and associa-
tion testing in the replication data set. These designs are
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compared with a single-stage family-based design in
which all available members are sequenced [12].
Methods of prioritization
Bayes factor criterion. Following the principles described
in Petersen et al [13], the probability that any particular
variant is causal under a given genetic model can be
estimated by accumulating likelihood ratio contributions
(the ratio of the likelihoods of the data under the alter-
native hypothesis that a particular variant is causal to
the likelihood under the null hypothesis that it is not
causal) across families. The likelihood ratio requires a
specific alternative hypothesis to be tested against the
null hypothesis, and estimation of these parameters is
likely to be highly unstable for rare variants. To avoid
this, Petersen et al [13] compute a Bayes factor (BF) by
averaging over a prior distribution of allele frequencies
and relative risks. BFs are computed as the ratio of the
conditional probabilities of the joint genotypes of the
sampled individuals under the true model to that under
the null.
Score test criterion. A simpler alternative to the BF cal-
culations for distinguishing causal from noncausal var-
iants was described by Ionita-Laza et al [14]. Because
score tests are computed under the null hypothesis, they
do not require specification of an alternative hypothesis
distribution of minor allele frequencies (MAFs) and rela-
tive risks (RRs) for causal alleles. Ionita-Laza et al com-
pute a score contribution for variants shared by each pair
of relatives, based on their population frequency and
degree of relationship, add these scores over all families,
and compare it to an approximate null mean and var-
iance. Here we explore an extension of this basic idea to
incorporate all available phenotype information in a pedi-
gree, including the phenotypes of subjects without
sequence data. We compute the score statistic:
Tv = f tfv = f (Yf − μf1)′−1f (Gfv − qv1)
= f (i∈Nfj∈Sf (Yfi − μf )−1fij (Gfjv − qv))
where Yf is the vector of phenotypes for family f; μf is
the family-specific mean phenotype; Ff is the kinship
matrix, that is, the matrix of kinship coefficients; Gfv is
the vector of genotypes for variant v; and qv is its
minor allele frequency. The Gfv-qv deviationsare set to
zero for untyped individuals, but the inclusion of the
kinship terms for typed-untyped pairs allows their phe-
notypes to contribute. This statistic has mean zero
under the null hypothesis and asymptotic variance var
(Tv) = ∑ftfv
2. Very similar tests have recently been
described by Schifano et al [15] and Chen et al [16]. For
the purpose of prioritizing variants, it is sufficient to cal-
culate the score test Tv
2/var(Tv) for each variant and
select the top-ranked ones at some cutoff. In other
simulations, we have found this statistic to be highly
correlated with the BF, to show nearly as good discrimi-
nation between causal and noncausal variants, and to be
computationally much faster.
Application to Genetic Analysis Workshop 18 data
We compared the various design and analysis alternatives
on a subset of the simulated Genetic Analysis Workshop
18 (GAW18) data. Based on the “answers” provided, we
chose to focus on the MAP4 region of chromosome 3,
which contains 15 functional variants having the stron-
gest associations with both diastolic blood pressure
(DBP) (6.5% of the total phenotypic variants) and systolic
blood pressure (SBP) (7.8%). These 15 variants spanned a
broad range of MAFs and effect sizes, individually
accounting for from 2.8% to <0.3% of the variance. We
selected all the variants in the region from 200 kilobases
(kb) upstream to 100 kb downstream of the transcription
start site (1151 variants in total). For comparison, we
selected six 300-kb regions at random from those on
chromosome 3 that harbored no functional variants for
either trait and included all variants in these regions
(6195 variants in total). For simplicity, we used the most
likely genotypes for the imputed individuals, although the
expected allele dosages would have been better. We also
limited our initial exploration to 1000 variants (all 15
functional and 985 of the null variants).
For each trait, we preprocessed the phenotype data
using a general linear mixed model to extract the inter-
cept and slope coefficients for age and their variances for
each individual, after adjustment for gender and current
hypertension treatment, with random effects for family.
These estimates were then treated as the phenotypes in
the genetic analysis of each variant individually, using lin-
ear regression.
For the single-stage design, we analyzed the associa-
tions using all 959 individuals using the quantitative
transmission disequilibrium test with mating-type means
(QTDTM) [17] and tabulated the proportion of functional
and nonfunctional variants that were associated at 0.05
significance after Bonferroni correction. We also tried
the FBAT-rare procedure [18,19], which is similar except
that the test is performed at the nuclear family level
rather than at the individual offspring level. Because of
the small number of informative nuclear families, the var-
iance estimator from this test was less stable. Because no
residual within-family dependency was simulated, the
QTDTM test is valid, so we present the results only from
this test.
For the 2-stage design, we first selected 2, 4, or 6 mem-
bers of each pedigree for whom sequencing data were
available, excluding those in the subset of maximally
unrelated individuals and the closely related full sib and
parent-offspring pairs. We used a logistic function of the
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squared rank deviation from the family’s median pheno-
type to select these members at random. We used the
sequence data on only these sampled individuals (along
with the complete phenotype data) to compute the score
test for each variant. In the second stage, we tested the
association of the top-ranked associations in the data set
of unrelated individuals using linear regression of the
phenotype on the genotype, with Bonferroni adjustment
for only the prioritized variants. We varied the thresholds
for prioritization from 0.5% to 16% of the top-ranked
variants.
Because of the computational burden, we restricted
these analyses to phenotype replicates 1 to 5 and ana-
lyzed each replicate using 20 random subsets of mem-
bers’ sequence data.
Results
Table 1 summarizes the results for 985 null and 15
functional variants in the MAP4 region for DBP and
SBP measurements, using the baseline observation,
intercept, and slope parameters as the phenotype. The
results for baseline and intercepts were generally similar
and somewhat stronger for SBP than for DBP, so subse-
quent analyses are presented only for SBP intercepts.
The mean scores showed a clear gradient in mean score
statistics between negative, null, and positive variants,
albeit with substantial overlap between their distribu-
tions (SDs about 1.0). Power was very low for both the
1-step and 2-step procedures, and generally the 1-step
procedure yielded higher power (13.3% vs. 4.0% when
restricted to the top 100 prioritized variants) despite the
larger multiple testing penalty. Slope estimates showed
opposite effects from intercepts and were generally very
weak, as might be expected as no effects on slopes were
simulated, only a shift in level. Extending this to all
6195 null variants lowered power for both 1-stage and
2-stage results, as expected, but the mean scores for the
null variants were then very close to zero.
Most of the 15 functional variants in MAP4 were
either very rare or had weak effects. Figure 1 compares
the 1-stage and 2-stage results, varying the number of
individuals whose sequence data was used for prioritiza-
tion. The 2 variants accounting for the largest variance
(2.79% and 1.49%) were significant in the QTDTM using
all the pedigree members in a single stage in 4 of the 5
replicates analyzed (80% power), while 1 variant with
only weak effects (0.05% of variance) was significant in 2
of 5 replicates; 2 other variants with relatively large
effects (1.43% and 1.11%) were not significant in any of
the 5 replicates. The first and second strongest variants
were prioritized 36%, 42%, and 55% of the time using 2,
4, and 6 subject’s sequence data, respectively, and the
majority of these were replicated. Three other variants–
1 with the third largest effect and 2 with very weak
effects–were prioritized with relatively large probabil-
ities, but none were ever replicated.
Discussion
With only 15 causal variants (most of them with very
small effects) in the subset of variants we analyzed, we
cannot reliably compare the power of the various
designs, although for these data, the 2-stage procedure
did not seem to perform better than the 1-stage proce-
dure. This may be partly a result of the small size of the
replication sample of unrelated individuals (N = 157).
As a test, we expanded the data set by combining the
unrelated individuals from 5 replicates for the second
step and the power for the joint test rose substantially
(results not shown). Despite the lower power of the 2-
stage approach, the cost is much lower because only a
small number of individuals need to be fully sequenced
and the genotyping required for replication is much
cheaper. Because the costs of sequencing and targeted
genotyping are rapidly changing and could be quite dif-
ferent for individual- and family-based designs, we have
not addressed cost-efficiency. See [12] and [20] for
Table 1 Mean score tests for the complete pedigrees.
Phenotype Parameter Mean score test Proportion of variants (%)
Prioritized Replicated 1-Stage QTDTM
Simulated - Null + Null +/- Null +/- Null +/-
DBP Baseline -1.42 -0.25 +0.42 10.2 14.7 1.8 5.3 1.7 9.3
Intercept -1.36 -0.32 +0.24 10.1 17.3 1.4 4.0 3.5 8.0
Slope +0.70 +0.14 -0.12 10.2 13.3 1.7 0.0 3.3 4.0
SBP Baseline -1.40 -0.35 +0.20 10.2 16.0 0.3 2.7 1.7 9.3
Intercept -1.34 -0.31 +0.37 10.1 17.3 0.0 4.0 2.0 13.3
Slope +0.85 +0.21 +0.11 10.2 12.0 0.5 0.0 2.3 0.0
Mean score tests for the complete pedigrees for protective, null, and deleterious variants, along with the proportion of the top 100 variants prioritized using only
the related members and replicated at a= 0.05/100 using only the unrelated members, and the proportion of variants significant at a= 0.05/1000 in a single-
stage QTDTM test. The “+” and “−” represent variants with positive and negative association with the phenotypes respectively. If higher blood pressure is
assumed to have more risk, “+” would correspond to deleterious variants and “−” would correspond to protective variants. In total, there are 6 deleterious
variants, 9 protective variants, and 961 noncausal variants being discovered and tested.
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discussion of optimization of sampling fractions for stu-
dies of independent individuals using individual and
pooled sequencing under cost constraints.
We arbitrarily fixed the total number of variants to be
prioritized at 100, but the general principles for design
of 2-stage designs [21-24] could be applied to optimize
the allocation of sample sizes across the 2 stages and
the threshold for prioritizing variants, subject to cost
constraints. As this threshold becomes more restrictive,
fewer variants will be selected, lowering power for the
first stage, but because the penalty for multiple testing
will be less, power for the second stage will be
improved; a similar tradeoff applies to sample size allo-
cation between the 2 stages. As a preliminary explora-
tion, we varied this threshold between 0.5% and 16% of
variants, and the overall power increased monotonically
with the threshold. Of course, the number of false posi-
tives also increased, but at a much lower rate, so that
the false discovery rate dropped with increasing thresh-
old and number of members sequenced. Still, the false
discovery rate is very large, so that a further replication
would be needed to weed out the false positives.
It is also possible that more appropriate adjustment for
time-dependent treatment data would improve power for
all these analyses (although it’s unlikely to affect the rela-
tive performance of the 1-stage and 2-stage designs).
Because treatment is itself related to blood pressure, it is
both a confounder and an intermediate variable on a cau-
sal pathway, so neither ignoring it nor covariate adjust-
ment is appropriate. This problem was extensively
discussed at Genetic Analysis Workshop 13 [25]; see refer-
ences [26-29] for discussion of several better approaches.
As a rough test of this hypothesis, we reran the analysis
using the simulated effect sizes for gender and treatment,
and the results (not shown) were essentially unchanged.
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